
0:00
3:19
In the first episode of The Biotech Brief, we break down what Yeztugo is, why it matters, how it compares to daily pills, and what this means for the $45 billion HIV prevention market.
More episodes from "The Biotech Brief"



Don't miss an episode of “The Biotech Brief” and subscribe to it in the GetPodcast app.







